Richter buys in trastuzumab biosimilar from DM Bio

31 October 2016

Gedeon Richter (RICHT: HB) has signed a technology transfer and license-in agreement with DM Bio for the development and commercialization of DM Bio's biosimilar monoclonal antibody, trastuzumab, the active ingredient of Swiss pharma giant Roche’s (ROG:SIX) cancer drug Herceptin.

According to the agreement, Richter, Hungary’s largest drugmaker, receives exclusive distribution rights for Europe, the CIS region and Latin American countries and it also obtains the pilot technology for further development.

Under the terms of the agreement Richter will make an upfront payment upon signature of the contract and further milestone payments will be made depending on the progress of the technology transfer and clinical program of the product. In addition, further sales related royalties will become payable to DM Bio subsequent to the launch of the product.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK